
Annual report 2025
added 02-19-2026
ICU Medical Revenue 2011-2026 | ICUI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ICU Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.23 B | 2.38 B | 2.26 B | 2.28 B | 1.32 B | 1.27 B | 1.27 B | 1.4 B | 1.29 B | 379 M | 342 M | 309 M | 314 M | 317 M | 302 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.38 B | 302 M | 1.18 B |
Quarterly Revenue ICU Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 537 M | 549 M | 605 M | - | 589 M | 596 M | 567 M | - | 553 M | 549 M | 569 M | - | 598 M | 561 M | 543 M | - | 336 M | 322 M | 318 M | 320 M | 319 M | 303 M | 632 M | 316 M | 307 M | 312 M | 331 M | 340 M | 327 M | 360 M | 372 M | 370 M | 343 M | 332 M | 248 M | 95.7 M | 97.1 M | 96.7 M | 89.9 M | 90.4 M | 86 M | 83.8 M | 81.5 M | 79.9 M | 77.5 M | 78.7 M | 73.2 M | 77.9 M | 82.8 M | 78.7 M | 74.3 M | 82.7 M | 81.4 M | 77.3 M | 75.5 M | 76.5 M | 76.5 M | 77.8 M | 71.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 632 M | 71.5 M | 278 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
iRhythm Technologies
IRTC
|
747 M | $ 122.35 | 0.73 % | $ 3.92 B | ||
|
Alcon
ALC
|
10.4 B | $ 75.8 | -0.08 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
41.1 M | $ 3.96 | -0.75 % | $ 183 M | ||
|
Ekso Bionics Holdings
EKSO
|
12.8 M | $ 10.99 | 1.48 % | $ 26.7 M | ||
|
The Cooper Companies
COO
|
4.09 B | $ 64.42 | -0.82 % | $ 12.8 B | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
Haemonetics Corporation
HAE
|
1.36 B | $ 59.93 | 0.52 % | $ 3.02 B | ||
|
electroCore
ECOR
|
32 M | $ 6.18 | -0.08 % | $ 52.4 K | ||
|
Envista Holdings Corporation
NVST
|
2.72 B | $ 26.8 | -0.89 % | $ 4.5 B | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
10.1 B | $ 482.22 | 0.71 % | $ 172 B | ||
|
Pulse Biosciences
PLSE
|
350 K | $ 23.02 | -5.07 % | $ 1.55 B | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 121.48 | 0.5 % | $ 5.88 B | ||
|
Microbot Medical
MBOT
|
117 K | $ 2.2 | 0.92 % | $ 101 M | ||
|
STAAR Surgical Company
STAA
|
239 M | $ 25.67 | 3.34 % | $ 1.27 B | ||
|
STERIS plc
STE
|
5.46 B | $ 221.8 | -0.77 % | $ 21.9 B | ||
|
Masimo Corporation
MASI
|
2.09 B | $ 178.63 | -0.04 % | $ 9.52 B | ||
|
Milestone Scientific
MLSS
|
8.97 M | $ 0.32 | -1.27 % | $ 26.3 M | ||
|
InfuSystem Holdings
INFU
|
110 M | $ 10.34 | 0.68 % | $ 214 M | ||
|
Stereotaxis
STXS
|
32.4 M | $ 1.93 | -1.53 % | $ 176 M | ||
|
Merit Medical Systems
MMSI
|
1.52 B | $ 68.58 | -0.04 % | $ 4.06 B | ||
|
Teleflex Incorporated
TFX
|
569 M | $ 136.56 | -0.07 % | $ 6.09 B | ||
|
Utah Medical Products
UTMD
|
9.04 M | $ 67.17 | -1.03 % | $ 218 M | ||
|
West Pharmaceutical Services
WST
|
3.07 B | $ 306.16 | -1.14 % | $ 22.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 11.91 | 0.08 % | $ 2.37 B | ||
|
Retractable Technologies
RVP
|
38.3 M | $ 0.65 | 0.2 % | $ 19.5 M | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 52.1 | 2.24 % | $ 171 M | ||
|
LeMaitre Vascular
LMAT
|
250 M | $ 113.45 | 0.49 % | $ 2.57 B | ||
|
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 21.38 | -1.57 % | $ 985 M | ||
|
Baxter International
BAX
|
11.2 B | $ 18.16 | -1.39 % | $ 9.32 B | ||
|
ResMed
RMD
|
3.58 B | $ 219.85 | 0.15 % | $ 32.1 B | ||
|
AtriCure
ATRC
|
535 M | $ 29.28 | 3.79 % | $ 1.4 B | ||
|
Harvard Bioscience
HBIO
|
86.6 M | $ 6.86 | 1.18 % | $ 305 M | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
292 M | $ 11.1 | -0.89 % | $ 453 M | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 152.14 | -1.74 % | $ 43.8 B | ||
|
Nephros
NEPH
|
14.2 M | $ 2.87 | 1.06 % | $ 29.8 M | ||
|
OraSure Technologies
OSUR
|
115 M | $ 3.0 | -1.64 % | $ 220 M | ||
|
Repligen Corporation
RGEN
|
632 M | $ 117.6 | 3.1 % | $ 6.55 M |